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The  results  of  skin  tests  with  the  type-specific polysaccharides 
(soluble specific substance or S.S.S.) of Types I, II and III pneumo- 
cocci in cases of lobar pneumonia receiving no specific therapy and in 
a group of patients suffering  from other diseases are reported elsewhere 
(1).  The  general  correlation of  the  positive  skin  reactions  to  the 
homologous S.S.S.  with  recovery  from  lobar  pneumonia offered  a 
possible method of observing and controlling specific antipneumococcic 
serum therapy.  The present study deals primarily with repeated skin 
tests in cases of lobar pneumonia treated with specific immune sera 
and a correlation of the results of these tests with circulating specific 
antibodies.  Another similar group of patients were studied for their 
skin reactions and circulating antibodies on a single occasion some time 
after recovery. 
In preliminary experiments it was found possible to  "produce" a 
positive skin test.  This was accomplished by the intravenous injec- 
tion of therapeutic immune serum in a normal individual who had no 
history of pneumonia and who gave negative skin tests with the 3 
types of specific pneumococcus polysaccharides.  The  skin reaction 
was elicited only by the specific carbohpdrate of the pneumococcus 
corresponding  in type to that of the antibody injected.  It was demon- 
strated after 5 cc. of concentrated Type I  antibody (Felton) and ap- 
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peared immediately after the injection of this amount.  The  reaction 
was again elicited after 6  hours, but not after 30 hours.  Some lots of 
serum  failed  to  give  this  response  with  the  same  or larger amounts. 
It  was  also  found  possible  in  cases  of  lobar  pneumonia  to  elicit 
positive cutaneous responses within a  few minutes after the injection 
of various amounts  of specific antisera. 
Materials and  Methods 
The patients upon whom these studies were made were, in general, similar to 
those used in the previous study (1) except that the present cases were treated with 
specific antipneumococcic sera.  In all, 31  cases were studied.  Felton's bivalent 
(Types I  and II) concentrated antibody solution was given to 17 Type I  and 11 
Type II cases; 3 of the former and 2 of the latter terminated fatally.  Convales- 
cent sera from homologous type cases were given to  1 Type II patient and to 2 
patients with Type III pneumonia.  All 3 of these patients died.  The age of the 
patients ranged from 13 to 76 years, 4 being under 20 and 2 over 60.  All but 4 
were males.  Only 3 of the 28 recipients of Felton's concentrated antibody solu- 
tion had a positive blood culture (J. O'B., Type I, and B. M., Type II, (Fig. 1) 
and a fatal Type II case) whereas all 3 of the convalescent serum recipients showed 
pneumococci in their blood.  Serum administration was begun in these cases from 
36 hours to the 8th day after the onset of the disease and all were acutely ill at the 
time the first dose was given. 
Skin  tests  were performed and  agglutinins  and  protective antibodies deter- 
mined as described in a  previous paper  (1).  Control skin tests with  the poly- 
saccharides were done and samples of the patients' blood were obtained 30 minutes 
or more before the first injection of serum.  Subsequently, skin tests were per- 
formed and blood sampJes were obtained before further injections of serum and at 
intervals during convalescence. 
Immune Sera.--A description of the materials and methods employed in  the 
administration of serum to the Type I  cases is given elsewhere (2).  The concen- 
trated sera used in these cases was furnished by the Antitoxin and Vaccine Labora- 
tory of the Massachusetts Department of Public Health through the courtesy of 
Dr. Benjamin White.  The concentrated antibody solution used in the treatment 
of the Type II cases of this series was prepared and supplied by Dr. Felton (3) of 
the  Department  of Preventive Medicine and Hygiene of the Harvard  Medical 
School and contained 2000  to 30()0 units (4) of mouse protection per cubic centi- 
meter against Types I  and II pneumococci.  The convalescent serum recipients 
were studied in the same manner as the other patients.  The methods used for 
preparing and  giving the  convalescent sera in  these  cases are  included in  the 
clinical report by Beebe and Sutliff (5).  Skin tests were done on the donors at the 
time that their blood was obtained, and their sera were tested for antibodies. 
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of response observed in the cases receiving no specific therapy (1) were seen in this 
group except that reactions  with edema of several hours duration were less common. 
Skin tests which showed no reaction for 30 minutes or more after injection, or 
skin tests,  which,  once positive, had already faded, sometimes gave a  typical 
response within a  few minutes following a  subsequent dose of serum.  In one 
instance (J. K., Type II), only the last of 7 skin tests done at I to 2 hourly intervals 
during the 1st day of treatment showed a positive Type II response.  The next 
skin test performed 16 hours later was positive with Types I and II S.S.S., and was 
followed, 2 minutes after the injection of the polysaccharide, by the appearance 
of blotchy wheals and erythema formations at the site of all previous injections of 
Types I and II S.S.S. 
Results in Cases of Type I and Type II Pneumonia Treated with Bivalent 
(Types I  and II) Concentrated Antibody Solution (Felton) 
First  Appearance  of Positive  Cutaneous  Reactions.--Observations 
were made before treatment in 20 of the 28 patients receiving Felton's 
serum.  In none was a positive response elicited to any of the 3 poly- 
saccharides injected.  The first skin test after the beginning of serum 
therapy was positive with the carbohydrate homologous to that of the 
disease in  14 of the 23  recovered cases.  This positive response was 
elicited in 10 of these 14 cases within 24 hours after the first dose of 
serum was given.  Of the 9 recovered cases whose first test after the 
institution of serum treatment was negative, 5 gave a positive homol- 
ogous response within 11 hours after the 1st dose, in the 6th the second 
test done the next day was positive, and in the 3 remaining patients a 
positive homologous response was never elicited. 
The  reaction  to  both  the  Type I  and the Type II polysaccharides 
usually became positive at the same  interval after serum administra- 
tion regardless of the type of the infecting pneumococcus.  The few 
exceptions may be seen by a  study of Fig.  1 on which  are represented 
graphically the results of all the skin tests done in the recovered cases 
treated with the concentrated antibodies. 
Relationship  between the First Appearance of the Positive Cutaneous 
Response and the Amount of Serum A dministered.--A positive response 
to the homologous S.S.S. was elicited in 10 of 13 patients tested after 
receiving amounts of serum up to 40 cc., and in 8 other patients at the 
time of the first test after the injection of serum, when more than 40 cc. 
had  already been given.  2  cases  that  showed doubtful or negative 656  REACTIONS  AND  ANTIBODIES  IN PNEU]~ONIA.  II 
responses  after small doses  showed positive reactions after  93  and 
85  cc., respectively.  The  frequency with which  positive  skin  tests 
were obtained after various doses of serum and at various intervals 
after its administration is shown graphically in Fig. 2. 
Duration  of  the  Skin  Reactivity  in  Serum  Treated Patients.--The 
frequency with which positive tests were elicited diminished rapidly 
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FIG. 1.  Results of repeated skin tests with the specific polysaccharide of Type I, 
II  and II  pneumococci in  14 Type I and 9 Type II  recovered  cases  of lobar  pneu- 
monia receiving  bivalent (Type I and II) concentrated pneumococcic antibodies 
(Felton). 
after the 3rd day following serum administration, as shown graphically 
in Fig. 2.  Only 2 of 9  cases in this series on whom  tests were done 
later than 1 month after recovery gave positive cutaneous responses to 
S.S.S. : a Type I  case on whom a positive Type II test was elicited at 
the end of the 4th month and a Type II case on whom both Type I 
and Type II S.S.S. gave positive reactions more than 8 months after MAXWELL ~'INLAND AND W.  D.  SUTLIFF  657 
serum treatment.  This diminution in the frequency of positive tests 
as  convalescence progressed was more  striking for the  reactions elic- 
ited by the Type I  S.S.S.  than for  those  obtained with  the Type II 
carbohydrate, regardless of whether the infecting organism was Type 
I or II. 
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Fro. 2.  Frequency of cutaneous  reactions,  agglutinins  and mouse protection at 
various intervals  in 23 recovered  cases of lobar pneumonia treated with bivalent 
(Type I and II) concentrated pneumococcic antibodies  (Felton). 
Skin Tests in Fatal Cases  and in  Cases  Recovering  with  Complica- 
tions.--A positive test was elicited in only 1 of 5 fatal cases receiving 
concentrated antibodies. 
This was obtained  in a Type II patient with the homologous S.S.S. 48 hours 
after the last dose of serum was given and 20 hours before the patient's death.  One 
of the fatal cases, from whose sputum Type I pneumococci were recovered at the 
time of admission to the hospital, was given a total of 335 cc. of concentrated serum 
in repeated doses over a period of a week and failed to give a positive response to 
any of the cutaneous  tests.  Blood cultures in this case were repeatedly negative. £ 
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Cultures at autopsy from each of the affected lobes of the lung, from several 
abscesses in these lobes and from both parotid glands, which were also abscessed, 
showed pure cultures of Staphylococcus  aureus, but no pneumococci. 
There was only i case in the series that developed a purulent compli- 
cation (J.O'B., Type I, see Fig. I).  This patient had positive Type I 
and II tests on the 2nd day after serum was given, but 5 days later the 
Type I  test was negative.  He had a  purulent infection of the left 
shoulder joint  from which Type I  pneumococci were recovered.  2 
patients with sterile pleural effusions (W. C. and L. S., Type I) showed 
the usual positive responses. 
Comparison of the Skin Response and Circulating Antibodies in Serum 
Treated Cases.--Agglutinins  were  studied in  the  sera of almost  all 
patients for all 3 types before and after serum administration.  Tests 
for protective antibodies against  Types I  and II were carried out in 
17 patients and for the homologous type alone in 7 other cases.  None 
of the patients tested showed agglutinins for any of the types before 
the onset of serum therapy.  In only 2 patients (J. K.,  Type II,  and 
F. R., Type I) were protective antibodies (against  100 lethal doses of 
Type I  in each case) found before treatment.  Fig. 2  shows graphi- 
cally the frequency with which cutaneous reactions, agglutinins and 
protective antibodies were demonstrated at various intervals. 
In 7 cases in which the antibodies were not first demonstrated simul- 
taneously, protective antibodies tended to appear first or at the same 
time that agglutinins were demonstrated, and the positive cutaneous 
responses, were subsequently elicited.  Later in the disease, the order 
in which the antibodies disappeared was not as regular as in the cases 
receiving no serum.  In general, protective antibodies tended to per- 
sist longer than agglutinins or skin reactivity, but 2 instances (R. H., 
Type I,  and B.  M.,  Type II)  were observed in which positive skin 
reactions were obtained without protective antibodies or agglutinins 
for the corresponding type.  There was but  one instance in  which 
agglutinins were present in the absence of corresponding protective 
antibodies.  The sera from many cases had protective antibodies with- 
out corresponding agglutinins.  5 cases were shown to have protective 
antibodies 2 months or more after recovery; all of these had Type II 
protection, and 2 had, in addition, Type I protection (J. K., Type II, 
and F. R., Type I). MAXWELL  FINLAND  AND  W.  D.  SUTLEPF  661 
The results of all the tests in 3 typical patients are shown graphically 
in Figs. 3 to 5. 
Variations in the Skin Response Following the Administratin of Vari- 
ous Lots of Serum.--The data on this subject are necessarily meager in- 
asmuch as several lots of serum were used and only a  small number of 
cases  treated  with  each  lot.  That  different  lots  may vary  in  their 
effect on the production of positive skin tests is suggested by experi- 
ences with 2 lots. 
Lot CPz,  containing 3500 units of mouse protection against Type I  and 1500 
units against Type II, was given to 4 Type I patients and 1 Type II patient all of 
whom recovered.  Positive tests with Types I and II S.S.S. were obtained with the 
first test following serum administration in 4 patients, only 1 of whom had received 
more than 35 cc. at that time.  One Type I case had a positive reaction to Type I 
S.S.S. after 35 cc., but a positive Type II test was never obtained.  Lot CP13, con- 
taining 3000 units against Type I and 1500 against Type II, was given to 3 Type I 
patients.  2 patients received 45 and 75 cc., respectively, yet failed to give positive 
reactions to either Type I  or Type II S.S.S.  The 3rd patient is not included in 
this series,  as complete immunological studies were not made.  He was treated 
with 180 cc. of the material on the 4th day of the disease, but failed to show any 
clinical improvement from the serum and died within 24 hours. 
Cutaneous Reactions in Cases of Type II and Type III Lobar Pneumonia 
Treated with Homologous Human Convalescent Serum 
3 patients received convalescent sera obtained from patients about 
1  week  after  recovery from  the  homologous  type  lobar  pneumonia. 
All the donors gave positive cutaneous reactions to the corresponding 
type S.S.S.,  and had demonstrable agglutinins  and  mouse protective 
antibodies in their sera. 
One of the recipients (P.M., Fig. 6), a Type II case who had negative skin tests, 
no demonstrable circulating antibodies and a negative blood culture before serum 
was given, showed a positive homologous skin test 1 hour after 130 cc. of serum was 
given.  At this time he also had demonstrable protective antibodies and aggiu- 
tinins for Type II pneumococci in his serum.  2 days later, no further serum having 
been given, his blood culture became positive for the first time, his skin tests were 
negative and no circulating antibodies were demonstrable, and the patient died. 
2 other patients, with Type III infection,  received 75 and 310 cc. of serum, respec- 
tively, but in neither was a positive response to Type III S.S.S. elicited,  nor were 
circulating antibodies demonstrated on repeated tests.  Both of these cases also 
ended fatally.  The patient receiving the larger doses had a  steadily increasing Positive 
skin tests 
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bacteremia in spite of the repeated doses  of serum.  He had,  before serum,  a 
strongly positive skin reaction to Type II S.S.S., and protection against 100 lethal 
doses of Type II pneumococci was demonstrated in his serum at that time.  The 
Type II positive skin reaction was repeatedly elicited and remained strongly posi- 
tive until 4 hours before death, at which time no wheal appeared but erythema of 
the same extent, but less intense, resulted.  Type II agglutinins were not found 
and Type II protective antibodies were not demonstrated after serum was given. 
TABLE  I 
Cutaneous Reactions with S.S.S. and Circulating Specific Antibodies in 3 Groups of 
Cases Treated with Felton's Serum 
Tests performed 10 to 
22 days after serum 
administration 
Tests 5 to 14 mos. after 
serum 
Cases  previously 
tested with S.S.S. 
Cases not previously 
tested 
No previous tests 
Protection 
present 
662 
Agglutinins 
present 
0 
-  No tests done. 
* Type II protection tests were done in only 15 of these cases. 
** One of the cases of empyema had positive reactions to Types I and II S.S.S. 
Protection tests were done in only 5 patients, all of whom had positive skin 
tests.  The 4 patients having positive Type I reactions had positive Type II skin 
tests as well. 
Single  Skin  Tests  and  Antibody  Studies  after  Serum  Administration 
It has previously been  shown  that  the  intracutaneous  injection  of 
the type-specific pneumococcus polysaccharides may result in the pro- 
duction  of  antibodies  specific  for  the  type  of  carbohydrate  injected 
(1, 6).  In order to learn whether this factor played a  significant r61e 
in the serum treated cases discussed above, 20 cases receiving Felton's 
serum were studied at a singl~e occasion after serum had been given. 
These  cases  may  be  divided  into  2  groups.  The  first group was 
studied  for skin reactions and  specific antibodies  10  to 22  days after 
serum  administration.  This  group  included  6  cases having  Type  I 
pneumonia  (2 of these had empyema at the time they were studied), MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  663 
2 with Type II and 1 with a miscellaneous pneumococcus infection. 
The second group  was studied 5 to 14 months after  recovery.  This group 
consisted of 11 Type I recipients of Felton's serum, including 2 patients 
who had empyema  and 2 others who had sterile pleural effusions follow- 
ing their disease.  The number of cases showing positive tests in these 
2 groups are shown in Table I.  In this table is also included a group 
of the cases previously described that received repeated skin tests and 
were again tested from 10 to 22 days after serum. 
In the group of cases tested for the first time during the 2nd or 3rd 
week after serum administration the incidence  of positive skin reactions, 
of agglutinins and of protective antibodies is not significantly  different 
from that found during the same period in the serum treated cases who 
had previously received several skin tests with the specific carbohy- 
drates. 
DISCUSSION 
The  observations  here  presented  demonstrate  the  possibility  of 
"producing" and maintaining for some time a positive response  in the 
human subject to the cutaneous injection of the purified, protein-free, 
type-specific carbohydrate of  the  pneumococcus.  This  is  accom- 
plished by the intravenous administration of the corresponding im- 
mune serum derived either from the horse or from the human patient 
after recovery from lobar pneumonia.  Previous observations by Cole 
(7), and more recently  by Sutliff (8), and by Lord and Persons (9), have 
indicated that demonstrable agglutinins and protective ant~odies may 
be produced and maintained in the blood of patients with lobar pneu- 
monia by the administration of sufficient amounts of potent immune 
sera.  These observations are here confirmed and extended to include 
the specific cutaneous response to the pneumococcus polysaccharides. 
The purified type-specific polysaccharide, although only a part of 
the pneumococcus  antigen, reacts specifically with antibodies produced 
by the whole antigen (10, 11).  Tillett and Francis (12) have further 
observed that the carbohydrate may induce a reaction in the skin of 
patients recovering from lobar pneumonia and that this reaction is 
specific for the type of infecl~ing  pneumococcus and is associated with 
the presence of agglutinins and precipitins in the sera of the patients. 
Attempts to  stimulate the production of antibodies by the purified 
carbohydrates have, however, failed (11, 13).  These substances have, 664  I~EACTIONS  AND  ANTIBODIES  IN  PNEIF~ONIA.  II 
therefore,  been  considered  non-antigenic  and  the  term  "haptenes" 
applied to them by Landsteiner (14, 15), has been generally accepted. 
More recently, however, it has been shown by Francis and Tillett(6) 
and in a previous communication (1) that these purified carbohydrates 
injected in minute amounts into the skin of patients ill with or recover- 
ing from lobar pneumonia and receiving no specific antisera are capable 
of stimulating the production of antibodies  specific for the  type of 
carbohydrafe injected.  Further observations  (16)  have shown that 
this is possible in normal individuals, suggesting the antigenic char- 
acter of these bacterial carbohydrates when used in this manner. 
The duration of the immune reactions  (Fig.  2)  in  serum  treated 
patients receiving repeated intracutaneous injections of polysaccharides 
appears  to  be  distinctly shorter  than  in  the  corresponding patients 
previously reported  (1).  In  the  former  group  such  reactions  were 
rarely found I month after recovery, whereas in the latter homologous 
and heterologous antibodies persisted for several months. 
These 2 groups of cases were in every respect comparable except for 
serum administration.  It may thus be inferred that the passive intro- 
duction  of  antibodies  in  patients  receiving  specific  polysaccharides 
intracutaneously  interferes  with  antibody  production  of  the  carbo- 
hydrates.  This is similar to the well recognized failure of individuals 
to develop effective  active immunity in other diseases following the 
intensive therapeutic use of antibacterial or antitoxic sera. 
The  results  here  presented  show  that,  in  most  instances,  cases 
terminating fatally after the administration of specific serum fail to 
give positive skin responses.  This failure to react apparently cannot 
always be interpreted as indicating a persistence of the type-specific 
pneumococcus infection.  That the failure of these fatal cases to react 
may be non-specific is suggested by the absence of positive reactions to 
the polysaccharides corresponding to the heterologous antibodies in- 
jected and by the failure of one patient to give a positive response to 
either the Type I  or the Type II polysaccharide although he had a 
massive infection with Staphylococcus aureus and  pneumococci could 
not be recovered from his organs at postmortem.  Inhibition of heterol- 
ogous skin reactions in  other  acute infections has been reported by 
others (17).  The almost complete absence of cutaneous reactions in 
these individuals is probably not due to the inability of the patients' MAXWELL  FINLAND  AND  W.  D.  SUTL1-F1  ~  665 
skin  to  react,  for typical reactions to  the  Type II  polysaccharides 
occurred in 3 cases terminating fatally (1 of these is reported in a pre- 
vious paper  (1)) and such patients were, in some instances, shown to 
respond to small doses of histamine with the characteristic wheal and 
erythema. 
Cases which failed to give characteristic positive reactions did not 
all  terminate  fatally.  The  failure  to  induce  positive  cutaneous 
responses by the injection of antisera in patients, in whom clinical bene- 
fit is otherwise obvious, may depend on the character of  the serum, 
some sera being more or less deficient in the quality of inducing cutane- • 
ous responses, or on the responsiveness of the patient.  Similar lack of 
reactivity in  some  normal  individuals  was  observed by  Coca  and 
Grove (18) in connection with the passive transfer of afopic reagins. 
The presence of foci of infection has not been constantly associated 
with the absence of skin responses.  About  one-half of the surviving 
patients with well established loci of pneumococcus infection persist- 
ing  after recovery from pneumonia,  both  with  and  without  serum 
treatment, showed cutaneous responses after  these foci were demon- 
strated. 
To attempt to define the curative dose of antipneumococcic sera on 
the basis of immune reactions in the patient is hazardous.  The general 
correlations, however, between the occurrence of positive skin  reac- 
tions and recovery, and between the dosage of immune sera and the 
appearance of the positive skin reaction are sufficiently  regular to be at 
least suggestive.  In the majority of the patients in this series who 
recovered and showed positive reactions, such reactions first appeared 
and were maintained after doses of 40  cc.  of Felton's  concentrated 
antibodies.  It is thus suggested that  the effective curative dose of 
most of the preparations used, perhaps only in the milder cases, is in 
the vicinity of this amount. 
The relationship of the skin test to agglutinins and protective anti- 
bodies has been discussed in a previous communication (1) and nothing 
further need be added here. 
SUMMARY  AND  CONCLUSIONS 
1.  Characteristic  cutaneous  responses to the type-specific protein- 
free carbohydrates of both Type I and Type II pneumococci have been 666  REACTIONS AND  ANTIBODIES IN  PNEUMONIA.  II 
"produced" in cases of lobar pneumonia due to either of these types 
by the intravenous injection of concentrated bivalent (Types I and II) 
antipneumococcic sera (Felton). 
2.  A  positive cutaneous response to the specific polysaccharide of 
Type II pneumococci has been passively transferred from human cases 
convalescing from this infection to a patient suffering from pneumonia 
due to this organism. 
3.  The cutaneous responses to the type-specific polysaccharides and 
circulating antibodies were studied in  51  cases of lobar pneumonia. 
Positive cutaneous reactions were, in most instances, associated with 
recovery, even when purulent complications were present.  Failure to 
elicit a positive reaction was usually followed by a fatal outcome. 
4.  The positive reactions in patients who were treated with concen- 
trated sera and recovered were most often elicited within 24 hours after 
the first dose and after a total of 40 ce. had been given. 
5.  The positive skin reactions obtained after the administration of 
specific antisera were associated with the presence of mouse protective 
antibodies and agglutinins in the sera of the patients. 
6.  The immune reactions in serum treated cases receiving repeated 
inoculations with the specific carbohydrates disappeared more rapidly 
than in similar cases receiving no antiserum.  It is suggested that the 
administration of antisera in some way interferes with the production of 
antibodies by the intracutaneously injected carbohydrates. 
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